OnKure Therapeutics, Inc.(OKUR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

OKUR OnKure Therapeutics, Inc.

未开盘 05-27 16:00:00 EDT

4.10

-0.02

-0.49%

盘后4.10

+0.000.00%

16:10 EDT

最高4.26	最低4.03	成交量31.68万
今开4.13	昨收4.12	日振幅5.58%
总市值1.66亿	流通市值1,874万	总股本4,040万
成交额133.40万	换手率6.93%	流通股本457.02万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"OKUR","market":"US","secType":"STK","nameCN":"OnKure Therapeutics, Inc.","latestPrice":4.1,"timestamp":1779912000000,"preClose":4.12,"halted":0,"volume":316792,"hourTrading":{"tag":"盘后","latestPrice":4.1,"preClose":4.1,"latestTime":"16:10 EDT","volume":184,"amount":754.4,"timestamp":1779912605022,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.004854368932038947,"floatShares":4570200,"shares":40395500,"eps":-4.326626,"marketStatus":"未开盘","change":-0.02,"latestTime":"05-27 16:00:00 EDT","open":4.13,"high":4.26,"low":4.03,"amount":1334023,"amplitude":0.055825,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.326626,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1779955200000},"marketStatusCode":0,"adr":0,"listingDate":1617940800000,"exchange":"NASDAQ","adjPreClose":4.12,"preHourTrading":{"tag":"盘前","latestPrice":4,"preClose":4.12,"latestTime":"04:00 EDT","volume":1,"amount":4,"timestamp":1779868824186,"change":-0.12,"changeRate":-0.029126,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":4.1,"preClose":4.1,"latestTime":"16:10 EDT","volume":184,"amount":754.4,"timestamp":1779912605022,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.300463},"requestUrl":"/m/hq/s/OKUR/tweets","defaultTab":"tweets","newsList":[{"id":"1179235499","title":"Onkure Therapeutics 宣布超额认购1.5亿美元私募融资，以推进新一代Pi3kα泛突变选择性抑制剂在乳腺癌及血管异常领域的研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1179235499","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179235499?lang=zh_cn&edition=full","pubTime":"2026-03-27 20:04","pubTimestamp":1774613094,"startTime":"0","endTime":"0","summary":"Onkure Therapeutics 近日公布一项获得超额认购的1.5亿美元私募融资计划，所筹资金将主要用于加速其新一代Pi3kα泛突变选择性抑制剂在乳腺癌和血管异常适应症中的临床开发进程。该融资得到多家知名投资机构支持，反映出市场对其创新疗法前景的强烈信心。\n公司表示，这笔资金将有力推动其核心候选药物走向临床后期研究，为相关疾病患者提供新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","OKUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2584560971","title":"Onkure Therapeutics, Inc.盘中异动 快速下挫5.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584560971","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584560971?lang=zh_cn&edition=full","pubTime":"2025-11-20 03:21","pubTimestamp":1763580106,"startTime":"0","endTime":"0","summary":"北京时间2025年11月20日03时21分，Onkure Therapeutics, Inc.股票出现异动，股价急速下跌5.29%。Onkure Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.12%。Onkure Therapeutics, Inc.公司简介：OnKure Therapeutics Inc是一家处于临床阶段的生物制药公司，专注于发现和开发顶级精准药物，针对现有疗法无法治疗的、经生物学验证的癌症驱动因素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251120032146950f06c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251120032146950f06c0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","LENZ","OKUR","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166519182","title":"OnKure Therapeutics, Inc.提交最高达2亿美元的混合上市申请 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=1166519182","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166519182?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:05","pubTimestamp":1763571936,"startTime":"0","endTime":"0","summary":"11月7日 - OnKure Therapeutics, Inc. :: *ONKURE THERAPEUTICS, INC.提交最高达2亿美元的混合上市申请 - SEC Filing","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","OKUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518746364","title":"奥本海默：维持OnKure Therapeutics(OKUR.US)评级，由优于大市调整至优于大市评级, 目标价由35.00美元调整至30.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518746364","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518746364?lang=zh_cn&edition=full","pubTime":"2025-03-11 20:41","pubTimestamp":1741696890,"startTime":"0","endTime":"0","summary":"奥本海默：维持OnKure Therapeutics(OKUR.US)评级，由优于大市调整至优于大市评级, 目标价由35.00美元调整至30.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/11204148668013.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["OKUR","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518789118","title":"OnKure Therapeutics(OKUR.US)：2024年Q4财报实现营收0美元；每股收益为-1.37美元，前值为-30.14美元，预期值为-0.74美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518789118","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518789118?lang=zh_cn&edition=full","pubTime":"2025-03-11 05:45","pubTimestamp":1741643101,"startTime":"0","endTime":"0","summary":"OnKure Therapeutics(OKUR.US)：2024年Q4财报实现营收0美元；每股收益为-1.37美元，前值为-30.14美元，预期值为-0.74美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/11054548643205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","OKUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104892081","title":"OnKure Therapeutics 2024年第四季度GAAP每股收益$(1.37)未达到$(0.74)的预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1104892081","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104892081?lang=zh_cn&edition=full","pubTime":"2025-03-11 04:14","pubTimestamp":1741637672,"startTime":"0","endTime":"0","summary":"OnKure Therapeutics(LENZ) (NASDAQ:OKUR)报告的季度每股亏损为$(1.37)，未达到分析师普遍预期的$(0.74)，低于预期85.14%。以上内容来自Benzinga Earnings专栏，原文如下：OnKure $Therapeutics(LENZ)$ (NASDAQ:OKUR) reported quarterly losses of $(1.37) per share which missed the analyst consensus estimate of $(0.74) by 85.14 percent.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","OKUR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.onkure.com;investors.onkuretherapeutics.com","stockEarnings":[{"period":"1week","weight":0.1517},{"period":"1month","weight":-0.1784},{"period":"3month","weight":0.5414},{"period":"6month","weight":0.3621},{"period":"1year","weight":0.8142},{"period":"ytd","weight":0.4138}],"compareEarnings":[{"period":"1week","weight":0.0124},{"period":"1month","weight":0.0493},{"period":"3month","weight":0.0887},{"period":"6month","weight":0.0981},{"period":"1year","weight":0.2695},{"period":"ytd","weight":0.1005}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"OnKure Therapeutics, Inc.于2014年9月22日在特拉华州注册成立。OnKure是一家临床阶段的生物制药公司，专注于发现和开发同类最佳的精准药物，这些药物针对可获得的疗法服务不足的癌症的生物验证驱动因素。使用基于结构的药物设计平台，OnKure正在构建一个强大的肿瘤不可知性候选药物管道，这些候选药物旨在实现最佳疗效和耐受性。OnKure正在开发OKI-219，一种选择性PI3K α H1047R抑制剂，作为其先导项目。OnKure的目标是成为靶向致癌PI3K α的领导者，并拥有多个旨在实现这一关键癌基因的同类最佳靶向的项目。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.092027},{"month":2,"riseRate":0.6,"avgChangeRate":-0.049012},{"month":3,"riseRate":0.6,"avgChangeRate":0.191785},{"month":4,"riseRate":0.6,"avgChangeRate":0.071237},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.139833},{"month":6,"riseRate":0.2,"avgChangeRate":-0.023429},{"month":7,"riseRate":0.4,"avgChangeRate":0.069083},{"month":8,"riseRate":0.4,"avgChangeRate":0.046264},{"month":9,"riseRate":0.6,"avgChangeRate":0.030016},{"month":10,"riseRate":0.8,"avgChangeRate":0.05116},{"month":11,"riseRate":0.2,"avgChangeRate":-0.152993},{"month":12,"riseRate":0.4,"avgChangeRate":-0.187777}],"exchange":"NASDAQ","name":"OnKure Therapeutics, Inc.","nameEN":"OnKure Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"OnKure Therapeutics, Inc.(OKUR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供OnKure Therapeutics, Inc.(OKUR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"OnKure Therapeutics, Inc.,OKUR,OnKure Therapeutics, Inc.股票,OnKure Therapeutics, Inc.股票老虎,OnKure Therapeutics, Inc.股票老虎国际,OnKure Therapeutics, Inc.行情,OnKure Therapeutics, Inc.股票行情,OnKure Therapeutics, Inc.股价,OnKure Therapeutics, Inc.股市,OnKure Therapeutics, Inc.股票价格,OnKure Therapeutics, Inc.股票交易,OnKure Therapeutics, Inc.股票购买,OnKure Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"OnKure Therapeutics, Inc.(OKUR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供OnKure Therapeutics, Inc.(OKUR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}